BBOT
BridgeBio Oncology Therapeutics Inc.NASDAQHealthcare$8.91-1.33%ClosedMarket Cap: $713.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.68
P/S
0.00
EV/EBITDA
-2.36
DCF Value
$11.88
FCF Yield
-13.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.5%
ROA
-29.9%
ROIC
-35.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-43.4M | $-38.8M | $-0.49 | — |
| FY 2025 | $0.00 | -Infinity% | $-145.8M | $-134.0M | $-4.30 | — |
| Q3 2025 | $0.00 | NaN% | $-49.2M | $-44.8M | $-1.90 | — |
| Q2 2025 | $0.00 | NaN% | $-30.1M | $-28.4M | $0.04 | — |
| Q1 2025 | $0.00 | NaN% | $-23.1M | $-22.1M | $-0.02 | — |
| Q4 2024 | $0.00 | NaN% | $-21.9M | $-19.7M | $0.12 | — |
| FY 2024 | $0.00 | NaN% | $-80.9M | $-74.3M | $0.46 | — |
| Q3 2024 | $0.00 | -Infinity% | $-19.7M | $-17.3M | $-0.74 | — |
| Q2 2024 | $0.00 | NaN% | $-23.9M | $-21.8M | $0.09 | — |
| Q1 2024 | $0.00 | NaN% | $-15.4M | $-15.4M | $0.05 | — |
| Q4 2023 | $0.00 | NaN% | $-41.7K | $-41.7K | $-0.00 | — |
| FY 2023 | $0.00 | NaN% | $-64.8M | $-64.7M | $-0.00 | — |